Infographic | March 24, 2022

Wearable Injectors: An Alternative To Traditional Intravenous Administration

  • The BD Libertas™ Wearable Injector is designed to deliver subcutaneous injections of large volume (2-5 mL or 5-10 mL) and/or high viscosity (up to 50 cP) fixed-dose complex biologics in home or clinical settings.1
  • The 2-5 mL device was evaluated in an early feasibility clinical study with a viscous placebo for its functional performance and tissue effects, pain tolerability and overall acceptability among 52 healthy participants.*2

This successful early feasibility clinical study of the BD Libertas™ Wearable Injector demonstrated consistent functional performance as designed with broad subject acceptability across all demographic categories (age, gender, BMI) and injection sites tested with or without ambulatory movement during injection. 

Results hold great promise for the future of subcutaneous chronic disease therapies, positioning the BD Libertas™ Wearable Injector as a viable alternative to traditional intravenous administration.*2

access the Infographic!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development

BD Medical - Pharmaceutical Systems